Compare Petróleo Brasileiro SA (PBR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Recursion Pharmaceuticals Inc — how do they compare? Petróleo Brasileiro SA trades at $24.9 (market cap $151.94B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Petróleo Brasileiro SA is far larger — about 71× Recursion Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PBR | RXRX | |
|---|---|---|
Market Cap | $151.94B | $2.14B |
Volume | 30,240,092 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $24.69 | $6.79 |
52-Week Low | $11.54 | $2.84 |
Typical Hold Time | 25 Days | 22 Days |
Enterprise Value | $212.36B | $1.66B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $23.99, up 0.8% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 6.24 and net income margin of 24.52%. Recent news highlights a new oil discovery off Amapa and the deployment of the P-80 platform, supporting production growth. Cash flow from operations remains robust at $36.05 billion for 2025, though 2026 projections show a net cash outflow.
The outlook is positive given low valuations, high profitability, and strategic expansions, but risks include volatile oil prices and political influence in Brazil. Analysts are generally bullish with a 50% buy rating and a consensus price target of $22.33, slightly below the current price, indicating potential near-term consolidation.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
